Silo Pharma's QwikAgents joins AMD AI Developer Program to enhance AI agent platform for various users and businesses.
Quiver AI Summary
Silo Pharma announced that its subsidiary, QwikAgents, has joined Advanced Micro Devices’ AMD AI Developer Program, which will provide access to resources such as AI development tools, cloud credits, and training to enhance the development of their AI agent platform. This collaboration is aimed at advancing QwikAgents' mission to make AI agents accessible to a variety of users, including individuals and businesses, with features for tasks like content generation and workflow automation. QwikAgents plans to utilize AMD's resources to improve platform performance and reliability, ultimately facilitating the deployment of autonomous AI agents capable of efficient task execution with minimal human intervention.
Potential Positives
- Silo Pharma's subsidiary, QwikAgents, has been accepted into the prestigious AMD AI Developer Program, providing access to advanced AI development tools and resources.
- Participation in the AMD program is expected to enhance QwikAgents' capabilities in developing and deploying AI agents, potentially improving performance and reliability.
- The QwikAgents platform aims to make powerful AI tools accessible to a wide range of users, including individuals and small businesses, at an affordable price point, which may expand the customer base.
Potential Negatives
- The press release emphasizes the company's participation in the AMD AI Developer Program, which may indicate that Silo Pharma relies heavily on external partnerships for technological advancements rather than demonstrating their own in-house capabilities.
- The focus on developing an AI-agent platform could divert attention and resources from the company's core biopharmaceutical goals, which may raise concerns about their strategic priorities and the potential for mission drift.
- Forward-looking statements contained in the release indicate uncertainty regarding the future performance and success of both Silo Pharma and its QwikAgents platform, suggesting potential risks that could affect investor confidence.
FAQ
What is Silo Pharma's focus area?
Silo Pharma focuses on addressing underserved conditions like stress-induced psychiatric disorders and chronic pain.
What does the AMD AI Developer Program offer to QwikAgents?
The program provides access to AI development tools, cloud credits, training resources, and a global developer community.
How does QwikAgents aim to support users?
QwikAgents aims to provide persistent AI agents for individuals, developers, and businesses with quick deployment and practical controls.
What features does the QwikAgents platform include?
The platform includes persistent memory, smart model routing, encrypted backups, and dedicated infrastructure for various AI applications.
What are the starting costs for QwikAgents' services?
Starter plans for QwikAgents begin at $14 per month, with scalable options for advanced workloads.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Hedge Fund Activity
We have seen 9 institutional investors add shares of $SILO stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC removed 333,733 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $120,043
- GEODE CAPITAL MANAGEMENT, LLC added 87,126 shares (+93.8%) to their portfolio in Q1 2026, for an estimated $31,339
- ADVISORSHARES INVESTMENTS LLC added 64,458 shares (+10.8%) to their portfolio in Q1 2026, for an estimated $23,185
- XTX TOPCO LTD removed 39,816 shares (-70.0%) from their portfolio in Q1 2026, for an estimated $14,321
- FNY INVESTMENT ADVISERS, LLC added 37,507 shares (+inf%) to their portfolio in Q2 2026, for an estimated $232,918
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 33,218 shares (+112.3%) to their portfolio in Q1 2026, for an estimated $11,948
- CITADEL ADVISORS LLC added 21,448 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,714
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ AMD AI Developer Program. Participation in the program provides access to AMD Developer Cloud credits, advanced AI development tools, training resources, and a global developer community designed to support and accelerate artificial intelligence innovation.
“Joining the AMD AI Developer Program represents what we believe is an important step in advancing our QwikAgents platform,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Access to AMD's AI development resources and cloud infrastructure can help accelerate our ability to develop, test, optimize, train and deploy AI agents across a wide range of use cases. We believe this collaboration and these resources should support QwikAgents’ mission to make powerful, persistent AI agents available not only to enterprises, but also to individual users , developers, and small businesses seeking affordable AI agent tools that are quick to deploy and designed with practical controls to support safer, more manageable use.”
QwikAgents is developing a next-generation AI agent platform designed to make dedicated, persistent AI agents accessible to individuals, developers, small businesses and enterprises. The platform is being designed to enable users to deploy blank and, soon, purpose-built agents for research, content generation, scheduling, coding, browser automation and workflow automation, with starter plans beginning at $14 per month and scalable infrastructure options for more advanced workloads. QwikAgents is also designed to combine persistent memory, dedicated agent infrastructure, smart model routing, and encrypted backups with a simple deployment process for users seeking configurable AI agents across personal, developer, and business workflows.
QwikAgents expects participation in the AMD AI Developer Program to support ongoing development, hosting, testing, optimization, benchmarking and potential training of AI agent workloads as the platform expands its capabilities across both consumer and business use cases. By leveraging access to AMD’s developer resources, QwikAgents aims to enhance platform performance, improve agent reliability and support scalable deployment of autonomous AI agents capable of reasoning, executing tasks and completing workflows with minimal human intervention.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories.
silopharma.com
About QwikAgents
QwikAgents, a wholly owned subsidiary of Silo Pharma, is an AI-agent platform designed to provide managed, purpose-built AI agents for individuals, developers, small businesses and enterprises. The platform supports use cases including research, content generation, scheduling, coding, browser automation and workflow automation. QwikAgents combines persistent memory, intelligent model routing, encrypted backups, dedicated compute resources and browser automation to support scalable AI-driven operations.
qwikagents.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
[email protected]
